Review The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs. In 2008, the next-generation NNRTI etravirine was approved for the trea...

Full description

Bibliographic Details
Main Author:	Nicolas Sluis-Cremer
Format:	Article
Language:	English
Published:	MDPI AG 2014-07-01
Series:	Viruses
Subjects:	HIV reverse transcriptase nonnucleoside inhibitors nevirapine efavirenz rilpivirine etravirine dapivirine MIV-150
Online Access:	http://www.mdpi.com/1999-4915/6/8/2960

Similar Items

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
by: Johnson Barry C, et al.
Published: (2012-12-01)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01)

Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring
by: Agata Paneth, et al.
Published: (2019-04-01)

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study
by: Danielle P. Porter, et al.
Published: (2015-12-01)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
by: Nicolas Sluis-Cremer, et al.
Published: (2013-11-01)

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy
by: Yuan Lei, et al.
Published: (2020-02-01)

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART
by: Jaime H. Vera, et al.
Published: (2019-08-01)

Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS
by: Anggriani Yusi, et al.
Published: (2019-08-01)

Me-Better Drug Design Based on Nevirapine and Mechanism of Molecular Interactions with Y188C Mutant HIV-1 Reverse Transcriptase
by: Yan Wang, et al.
Published: (2022-10-01)

Adverse pregnancy outcomes associated with antiretroviral therapy initiated before pregnancy and during pregnancy: a retrospective study in Hubei province, China
by: Yuting Tan, et al.
Published: (2023-05-01)

Large Multidomain Protein NMR: HIV-1 Reverse Transcriptase Precursor in Solution
by: Tatiana V. Ilina, et al.
Published: (2020-12-01)

Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study
by: Bih Hycenta Chendi, et al.
Published: (2019-02-01)

Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility
by: Tomasz Frączek, et al.
Published: (2018-01-01)

Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial
by: Adrian Curran, et al.
Published: (2020-04-01)

Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach
by: Mahta Mansouri, et al.
Published: (2023-03-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review
by: Olga Tarasova, et al.
Published: (2018-05-01)

Efavirenz challenge in patients with nevirapine induced Stevens-Johnson Syndrome
by: Thandekile C. Manzini, et al.
Published: (2016-12-01)

Delay of cell growth and loss of stemness by inhibition of reverse transcription in human mesenchymal stem cells derived from dental tissue
by: Won-Cheol Lee, et al.
Published: (2019-09-01)

Asymmetric conformational maturation of HIV-1 reverse transcriptase
by: Xunhai Zheng, et al.
Published: (2015-06-01)

Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region
by: Tao Zhang, et al.
Published: (2022-11-01)

The role of rilpivirine in Southern Africa
by: Michelle A. Moorhouse, et al.
Published: (2019-05-01)

Revisiting efavirenz in the era of dolutegravir: Low-dose efavirenz, a viable alternative capable of holding its own against dolutegravir-based regimens
by: Sumit Arora, et al.
Published: (2023-01-01)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
by: Sanjeev Sinha, et al.
Published: (2017-12-01)

Abnormal coagulation profile in people living with HIV-AIDS on combined Antiretroviral Therapy: findings from a case-control study in the Ho municipality, Ghana
by: Richard Kobina Dadzie Ephraim, et al.
Published: (2018-02-01)

Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity
by: Ana Luiza Chaves Valadão, et al.
Published: (2015-06-01)

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
by: Anna Figueiredo, et al.
Published: (2006-11-01)

<i>Cis</i>-Allosteric Regulation of HIV-1 Reverse Transcriptase by Integrase
by: Takao Masuda, et al.
Published: (2022-12-01)

Identification of anti-HIV and anti-Reverse Transcriptase activity from Tetracera scandens
by: Hyeok Sang Kwon, et al.
Published: (2012-03-01)

Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
by: Kamal Singh, et al.
Published: (2019-04-01)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

Mutation Rates and Intrinsic Fidelity of Retroviral Reverse Transcriptases
by: Luis Menéndez-Arias
Published: (2009-12-01)

Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
by: Anthi Petrou, et al.
Published: (2019-10-01)

The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance
by: Scott J. Garforth, et al.
Published: (2014-10-01)

Anthrarufin and Its Anionic Moieties as Potential Inhibitors of HIV-1 Reverse Transcriptase (RT)
by: Svetlana Jeremić, et al.
Published: (2022-11-01)

2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
by: M. Matilde Marques, et al.
Published: (2013-04-01)

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis
by: Thanh Truong Giang Ly, et al.
Published: (2022-01-01)

Molecular Docking Studies of Marine Diterpenes as Inhibitors of Wild-Type and Mutants HIV-1 Reverse Transcriptase
by: Alessandra M. T. de Souza, et al.
Published: (2013-10-01)

Reverse transcriptase inhibition: a way to defeat HIV
by: Vikas Kumar, et al.
Published: (2022-01-01)